J Cardiovasc Interv.  2022 Apr;1(2):53-60. 10.54912/jci.2021.0006.

Clinical Outcomes Following SYNERGY Stent Implantation in a Prospective All-Comers Registry

• Yun KH
• Cho JY
• Lee SY
• Oh SK
• Lee SR
• Park JP

• KMID: 2561242
• DOI: http://doi.org/10.54912/jci.2021.0006

Abstract

Background
The SYNERGY stent is a thin-strut (74 µm) platinum chromium metal alloy stent that elutes everolimus from an ultrathin (4 µm) bioabsorbable polymer applied to only the abluminal surface. Although, the efficacy and safety of the SYNERGY stent have been demonstrated in randomized trials, the results of real-world practice were limited.
Methods
This study is a prospective, all-comers, single-arm registry conducted across 3 centers in South Korea from May 2016 to December 2019. The primary endpoint was 12-momth target vessel failure (TVF) defined as cardiac death, target vessel myocardial infarction (MI), and target vessel revascularization (TVR).
Results
A total of 703 patients with successful SYNERGY stent implantations were enrolled in this registry. TVF at 12 months was observed in 2.4% of the patients after SYNERGY stent implantation. The individual rate of cardiac death, target vessel MI, and TVR was 1.4%, 0.3%, and 1.0%, respectively. Stent thrombosis occurred in 3 patients (0.4%) during 12-month follow-up. Multivariate analysis showed long stent implantation was an independent predictor of 12-month TVF (hazard ratio, 2.97; P = 0.027).
Conclusions
The use of the SYNERGY stent was associated with a low incidence rate of 12-month TVF in the real-world, all-comers percutaneous coronary intervention population.

Keyword

Percutaneous coronary intervention; Drug-eluting stents; Registries; Treatment failure